Enovis releases AltiVate Reverse Glenoid System

Enovis introduced the one-tray AltiVate Reverse Glenoid System, which expands the glenoid implant offering of the market-leading AltiVate Reverse to include modular, augmented baseplates. Based on the Company’s central screw fixation design with a minimum of 10 years of clinical follow-up1, the AltiVate Reverse Glenoid System received FDA 510(k) clearance in May 2024 for use in reverse shoulder arthroplasty, including revisions, making it an important addition to Enovis’ industry-leading AltiVate products. “We are very pleased to offer a modular, augmented baseplate based on the proven central screw fixation principle of our legacy Reverse Shoulder Prosthesis system,” said Louie Vogt, Group President of Enovis(TM) Reconstructive Business Group. “This addition to our market-leading AltiVate Reverse continues our long history of surgeon-driven innovation and commitment to exceptional patient outcomes.”